Article: [(18)F]fluoroacetate positron emission tomography for hepatocellular carcinoma and metastases: an alternative tracer for [(11)C]acetate?
| Title | [(18)F]fluoroacetate positron emission tomography for hepatocellular carcinoma and metastases: an alternative tracer for [(11)C]acetate? |
|---|---|
| Authors | Ho, CL1 2 Cheung, MK1 2 Chen, S1 2 Cheung, TT1 2 Leung, YL1 2 Cheng, KC1 2 Yeung, WD1 2 |
| Issue Date | 2012 |
| Publisher | BC Decker Inc. |
| Citation | Molecular Imaging, 2012, v. 11 n. 3, p. 229-239 [How to Cite?] DOI: http://dx.doi.org/10.2310/7290.2011.00043 |
| Abstract | [11C]Acetate (ACT) positron emission tomography/computed tomography (PET/CT) is useful in the detection of hepatocellular carcinoma (HCC). This study aimed to evaluate whether [18F]fluoroacetate (FAC) could be an alternative analogue of [11C]ACT for the diagnosis of HCC. [18F]FAC was synthesized using the precursor t-butyl 2-(methanesulfonyloxy)ethanoate. Five volunteer patients with known HCC were recruited after consent. Whole-body [18F]FAC PET/CT was performed at 20 minutes and 1 hour postinjection and compared to [11C]ACT PET/CT at 20 minutes postinjection to assess biodistribution and tumor uptake characteristics. Qualitative and semiquantitative analyses were performed with statistical correlations on the physiologic organs of accumulation and HCC lesions for both tracers. [18F]FAC was obtained with 99% radiochemical purity, and the reaction yield was 16.0% with 1-hour synthesis time. The biodistribution of [18F]FAC on PET/CT was significantly different from that of [11C]ACT (p < .05) by the lack of preferential uptake in any specific organ, particularly the pancreas, resembling the pattern of blood-pool retention although partly metabolized via the bowel. There was no significant defluorination, and none of the [11C]ACT-avid HCC lesions showed increased [18F]FAC activity. These were different from the results reported on other species. [18F]FAC may not be a potential alternative tracer for [11C]ACT in PET/CT evaluation of HCC in human subjects. |
| ISSN | 1535-3508 2011 Impact Factor: 3.18 2011 SCImago Journal Rankings: 0.359 |
| DOI | http://dx.doi.org/10.2310/7290.2011.00043 |
| dc.contributor.author | Ho, CL |
|---|---|
| dc.contributor.author | Cheung, MK |
| dc.contributor.author | Chen, S |
| dc.contributor.author | Cheung, TT |
| dc.contributor.author | Leung, YL |
| dc.contributor.author | Cheng, KC |
| dc.contributor.author | Yeung, WD |
| dc.date.accessioned | 2012-02-03T06:15:05Z |
| dc.date.available | 2012-02-03T06:15:05Z |
| dc.date.issued | 2012 |
| dc.description.abstract | [11C]Acetate (ACT) positron emission tomography/computed tomography (PET/CT) is useful in the detection of hepatocellular carcinoma (HCC). This study aimed to evaluate whether [18F]fluoroacetate (FAC) could be an alternative analogue of [11C]ACT for the diagnosis of HCC. [18F]FAC was synthesized using the precursor t-butyl 2-(methanesulfonyloxy)ethanoate. Five volunteer patients with known HCC were recruited after consent. Whole-body [18F]FAC PET/CT was performed at 20 minutes and 1 hour postinjection and compared to [11C]ACT PET/CT at 20 minutes postinjection to assess biodistribution and tumor uptake characteristics. Qualitative and semiquantitative analyses were performed with statistical correlations on the physiologic organs of accumulation and HCC lesions for both tracers. [18F]FAC was obtained with 99% radiochemical purity, and the reaction yield was 16.0% with 1-hour synthesis time. The biodistribution of [18F]FAC on PET/CT was significantly different from that of [11C]ACT (p < .05) by the lack of preferential uptake in any specific organ, particularly the pancreas, resembling the pattern of blood-pool retention although partly metabolized via the bowel. There was no significant defluorination, and none of the [11C]ACT-avid HCC lesions showed increased [18F]FAC activity. These were different from the results reported on other species. [18F]FAC may not be a potential alternative tracer for [11C]ACT in PET/CT evaluation of HCC in human subjects. |
| dc.description.nature | Link_to_subscribed_fulltext |
| dc.identifier.citation | Molecular Imaging, 2012, v. 11 n. 3, p. 229-239 [How to Cite?] DOI: http://dx.doi.org/10.2310/7290.2011.00043 |
| dc.identifier.doi | http://dx.doi.org/10.2310/7290.2011.00043 |
| dc.identifier.epage | 239 |
| dc.identifier.hkuros | 198329 |
| dc.identifier.issn | 1535-3508 2011 Impact Factor: 3.18 2011 SCImago Journal Rankings: 0.359 |
| dc.identifier.issue | 3 |
| dc.identifier.pmid | 22554487 |
| dc.identifier.scopus | eid_2-s2.0-84862661268 |
| dc.identifier.spage | 229 |
| dc.identifier.uri | http://hdl.handle.net/10722/144590 |
| dc.identifier.volume | 11 |
| dc.language | eng |
| dc.publisher | BC Decker Inc. |
| dc.publisher.place | Canada |
| dc.relation.ispartof | Molecular Imaging |
| dc.subject.mesh | Carcinoma, Hepatocellular - pathology - radionuclide imaging |
| dc.subject.mesh | Fluorine Radioisotopes - diagnostic use - pharmacokinetics |
| dc.subject.mesh | Liver Neoplasms - pathology - radionuclide imaging |
| dc.subject.mesh | Neoplasm Metastasis - radionuclide imaging |
| dc.subject.mesh | Positron-Emission Tomography and Computed Tomography - methods |
| dc.title | [(18)F]fluoroacetate positron emission tomography for hepatocellular carcinoma and metastases: an alternative tracer for [(11)C]acetate? |
| dc.type | Article |
Author Affiliations
- The University of Hong Kong
- Hong Kong Sanatorium and Hospital